Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next Step for Onyx Pharma: 2011 Is Defining Year

Executive Summary

Onyx Pharmaceuticals Inc.’s growing pipeline, including one high-profile compound finishing successful Phase II clinical trials, appears to be finally moving the company beyond its considerable reliance on its flagship cancer drug Nexavar (sorafenib).

You may also be interested in...



Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy

Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.

Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy

Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.

Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy

Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.

Related Content

Topics

UsernamePublicRestriction

Register

PS053061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel